All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2006-003682-14 | Randomised phase II study on the treatment with pegfilgrastim after autologous blood stem cell transplantation | 2014-01-25 | due-trials |
Reported results | 2006-003683-54 | Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Granzkörperbestrah... | 2013-07-03 | due-trials |
Reported results | 2007-001262-32 | Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung canc... | 2012-10-12 | due-trials |
Completed, but no date, and reported results | 2007-003945-33 | A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Randomis... | bad-data | |
Reported results | 2008-001405-41 | A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) | 2013-02-28 | due-trials |
Exempt, with results | 2008-003829-16 | An open, randomized clinical phase I/II trial to investigate maximum tolerated dose, efficacy, and safety of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide co... | 2016-10-24 | not-yet-due |
Reported results | 2008-004083-39 | The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma | 2020-01-31 | due-trials |
Exempt, with results Terminated | 2009-010824-25 | Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, High-dose... | 2015-04-28 | not-yet-due |
Reported results Terminated | 2009-014677-41 | CHAMP – An open-label, randomised, multicentre, phase II clinical study of panitumumab plus pemetrexed and cisplatin (PemCisP) versus PemCis in the first-line treatment of patients with stage IIIB or ... | 2013-11-05 | due-trials |
Reported results | 2009-015119-42 | An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versu... | 2012-03-28 | due-trials |
Ongoing, reported early | 2009-016782-28 | Panitumimab in combination with radiotherapy in patients with locally advanced RAS wildtype rectal cancer (clinical stages II and III) | not-yet-due | |
Reported results | 2009-018025-73 | Randomised phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- or third-line treatment of patients with metastatic breast cancer | 2014-07-19 | due-trials |
Reported results | 2010-018339-16 | CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A prospective, multi-center, phase IV study to assess the compliance in patients with Philadelphia chromosome-posi... | 2013-07-03 | due-trials |
Completed, but no date, and reported results | 2010-018849-59 | A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancer Eine randomisierte Phase II-Studie zu einer Stan... | bad-data | |
Reported results Terminated | 2010-019564-37 | A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects with Metastatic Colorectal Carcinoma Receiving Panitumumab Eine doppelblinde, placebo... | 2013-05-14 | due-trials |
Reported results | 2010-023630-24 | Phase II open-label pilot study evaluating the safety and efficacy of Certican ® (everolimus) in the prevention of chronic graft-versus-host disease and late pulmonary complications after allogeneic h... | 2017-05-03 | due-trials |
Completed, but no date, and reported results Terminated | 2013-002564-69 | Double-blind, placebo-controlled multicenter phase II trial to evaluate the efficacy and safety of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in subjects with relapsed o... | bad-data | |
Listed as ongoing, but also has a completion date and reported results | 2013-004328-12 | Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia - the EUROPE-trial | 2021-07-01 | bad-data |